Cargando…

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide. In patients with HCC, histopathogical differentiation is an important indicator of prognosis; however, because determination of HCC differentiation is difficult, the recently described immunohistochemical (IHC) marker glypic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaseb, Ahmed Omar, Hassan, Manal, Lacin, Sahin, Abdel-Wahab, Reham, Amin, Hesham M., Shalaby, Ahmed, Wolff, Robert A., Yao, James, Rashid, Asif, Vennapusa, Bharathi, Feng, Janine, Ohtomo, Toshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342524/ https://www.ncbi.nlm.nih.gov/pubmed/27655712 http://dx.doi.org/10.18632/oncotarget.12066

Ejemplares similares

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
por: Ali, Mahmoud A, et al.
Publicado: (2017)

Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2015)

Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study
por: Lacin, Sahin, et al.
Publicado: (2020)

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
por: Pestana, Roberto Carmagnani, et al.
Publicado: (2018)

Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas
por: Yorita, Kenji, et al.
Publicado: (2019)

Origin and role of hepatic myofibroblasts in hepatocellular carcinoma
por: Yavuz, Betul Gok, et al.
Publicado: (2020)

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2015)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma
por: Niekamp, Andrew, et al.
Publicado: (2018)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development
por: Haque, Abedul, et al.
Publicado: (2022)

Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas
por: El-Saadany, Sherif, et al.
Publicado: (2018)

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Mohamed, Yehia I., et al.
Publicado: (2021)

Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma
por: Kaseb, Ahmed O., et al.
Publicado: (2022)

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients
por: Mohamed, Yehia I., et al.
Publicado: (2022)

Editorial: charting the future of hepatocellular carcinoma publications
por: Kaseb, Ahmed Omar
Publicado: (2018)

Glypican 3-Targeted Therapy in Hepatocellular Carcinoma
por: Nishida, Takahiro, et al.
Publicado: (2019)

Association of dietary fat intake and hepatocellular carcinoma among US adults
por: Moussa, Iman, et al.
Publicado: (2021)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer
por: Dandachi, Dima, et al.
Publicado: (2018)

Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults
por: Moussa, Iman, et al.
Publicado: (2021)

The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer
por: Lacin, Sahin, et al.
Publicado: (2020)

Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma
por: Bell, Meghan M., et al.
Publicado: (2020)

Welcome to Journal of Hepatocellular Carcinoma
por: Kaseb, Ahmed O
Publicado: (2015)

Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
por: Kaseb, Ahmed O., et al.
Publicado: (2014)

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma
por: Chamseddine, Shadi, et al.
Publicado: (2023)

Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis
por: Xiao, Wei-Kai, et al.
Publicado: (2014)

Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma
por: Lee, Hyun Jung, et al.
Publicado: (2014)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma
por: Zhang, Yi-Fan, et al.
Publicado: (2016)

Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis
por: Sun, Bin, et al.
Publicado: (2017)

Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
por: Guo, Meng, et al.
Publicado: (2020)

Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma(☆)
por: Shih, Tsung-Chieh, et al.
Publicado: (2020)

Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
por: Zheng, Xiufeng, et al.
Publicado: (2022)

Association between microRNA-527 and glypican-3 in hepatocellular carcinoma
por: Nomura, Kei, et al.
Publicado: (2021)

Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma—A Narrative Review
por: Chamseddine, Shadi, et al.
Publicado: (2023)

Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance
por: Khalaf, Ahmed M, et al.
Publicado: (2018)

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis
por: Liu, Hong, et al.
Publicado: (2018)

Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector
por: Liu, Quan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bvsnbl998to7bm4b8rmg6c7fra